The REPEAT Trial: Regorafenib in Combination With Paclitaxel in Advanced Oesophagogastric Carcinoma, a Phase 1b Study
Phase of Trial: Phase I/II
Latest Information Update: 29 Jul 2016
At a glance
- Drugs Regorafenib (Primary) ; Paclitaxel
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions
- Acronyms REPEAT
- 26 Jul 2016 Planned End Date changed from 1 Apr 2018 to 1 Mar 2018.
- 26 Jul 2016 Planned primary completion date changed from 1 Apr 2017 to 1 Mar 2018.
- 26 Jul 2016 Status changed from not yet recruiting to recruiting.